NEW YORK (GenomeWeb News) — Promega and China’s Guangzhou Institute of Biomedicine and Health plan to co-develop drug-screening assays, the company said today. 
 
Under the agreement, GIBH researchers will use Promega’s drug-screening assays to develop tests for Cytochrome P450, Kinase, and GPCR profiling.
 
Promega said GIBH, which is part of the Chinese Academy of Sciences, will use the assays for their own research and will offer them through contracts to other companies.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.